Krystal Biotech (KRYS) announced that the United States Food and Drug Administration granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 viral vector used in the Company’s redosable eye drop gene therapy KB801, currently under evaluation in a randomized placebo controlled trial for the treatment of neurotrophic keratitis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments
- Buy Rating for Krystal Biotech Driven by Vyjuvek’s Expanded Label and Market Potential
- Krystal Biotech announces FDA approval of update VYJUVEK label
- 3 ‘Outperform’ Healthcare Stocks, According to AI Analyst, 9/10/25
- Krystal Biotech price target lowered to $216 from $219 at Chardan